SLC5A2 and Hyperglycemia: Inhibition of SGLT2 decreases glucose reabsorption and, thus, increases urinary glucose excretion, leading to a reduction in both fasting and postprandial hyperglycemia, preventing glucotoxicity and hyperglycemia-induced damage [51,52].